Acumen Pharmaceuticals (ABOS) Accounts Payables (2020 - 2026)

Acumen Pharmaceuticals (ABOS) has 7 years of Accounts Payables data on file, last reported at $1.7 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 56.72% year-over-year to $1.7 million; the trailing twelve-month figure through Mar 2026 stood at $1.7 million (up 56.72% YoY), and the FY2025 full-year result was $554000.0, down 90.19% from the prior year.
• Accounts Payables grew to $1.7 million in Q1 2026, from $554000.0 in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $5.6 million in Q4 2024 to a low of $554000.0 in Q4 2025.
• A 5-year average of $2.0 million and a median of $1.7 million in 2026 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables surged 445.55% in 2022 and slumped 90.19% in 2025, its largest moves.
• Tracing ABOS's Accounts Payables over 5 years: stood at $1.6 million in 2022, then retreated by 15.91% to $1.4 million in 2023, then soared by 309.57% to $5.6 million in 2024, then tumbled by 90.19% to $554000.0 in 2025, then jumped by 198.74% to $1.7 million in 2026.
• Business Quant data shows ABOS's Accounts Payables at $1.7 million in Q1 2026, $554000.0 in Q4 2025, and $682000.0 in Q3 2025.